Solobacterium moorei

(aka Bulleidia moorei)

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Solobacterium moorei, (aka Bulleidia moorei), is a Gram-positive, non-spore-forming, strictly anaerobic, non-motile, rod-shaped bacterium. It has been detected in at least 14 gut microbiome compilation studies or metastudies. The DNA G+C content is 37-39%. Solobacterium moorei is probably a common, although minor, coloniser of the gut. (Kageyama2000c; Kageyama2011Bergey)



  • This organism has been recovered from human faeces and blood. The risk classification (www.baua.de) for this organism is 1, i.e., low risk of infection and spread. Pathogenicity status unknown, or very unlikely to be pathogenic. Is a known gut commensal.
    • GENERAL CHARACTERISTICS (Kageyama2000c); (Kageyama2011Bergey);
    Character Response
  • Substrates hydrolysed or digested:
  • aesculin;
  • 🌡
  • Temperature tolerance:
  • grows at 37℃;
  • H+
  • Acid from carbohydrates usually produced:
  • fructose; galactose; glucose; ribose; maltose;
  • Active enzymes:
  • acid phosphatase; α-glucosidase; Leu arylamidase;
    • SPECIAL FEATURES (Kageyama2000c); (Kageyama2011Bergey);
    Character Response
  • ✓
  • Metabolites produced:
  • acetate (major); butyrate; lactate; pyruvate (minor);
  • ✗
  • Metabolites not produced:
  • H₂S; indole;
  • ✗
  • VP test:
  • not active
  • ✗
  • Nitrate:
  • not reduced
    • RESPONSE TO ANTIBIOTICS (Goldstein2018a); (Goldstein2013b); (Tyrrell2012); (Citron2012a);
    Class Active Resistant
  • Penicillins:
  • ampicillin; ampicillin-sulbactam; imipenem; meropenem; piperacillin-tazobactam;
  • Cephalosporins:
  • cefoxitin;
  • ceftazidime;
  • Tetracyclines:
  • tigecycline;
  • Quinolines:
  • moxifloxacin;
  • Heterocycles:
  • metronidazole;
  • Vancomycins:
  • vancomycin;
  • Miscellaneous antibiotics:
  • clindamycin; linezolid;

  • Kageyama, A., & Benno, Y. (2000d). Phylogenic and phenotypic characterization of some Eubacterium-like isolates from human feces: description of Solobacterium moorei Gen. Nov., Sp. Nov. Microbiology and Immunology, 44(4), 223–227.

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Firmicutes Class:  Erysipelotrichia Order:  Erysipelotrichales Family:  Erysipelotrichaceae Genus:  Solobacterium Alt. name:  Bulleidia moorei Gram stain:  + O2 Relation.:  strictly anaerobic Spore:  No spore Motility:  Sessile Morphology:  Rod
    Health:  Unknown
    Source:  human faeces and blood
    DNA G+C(%):  37-39
    Mid T(℃):  37(+)
    		Aesculin:  + Urea:  neg Gelatin:  neg Starch:  neg Hippurate:  neg
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    Arabinose:  neg L-Arabinose:  neg Fructose:  + Galactose:  + Glucose:  + Mannose:  neg Rhamnose:  neg Ribose:  + D-Tagatose:  neg Xylose:  neg Cellubiose:  neg Lactose:  neg Maltose:  + Melezitose:  neg Sucrose:  neg Trehalose:  neg Amygdalin:  neg Dextrin:  neg Aesculin:  neg Glycogen:  neg Starch:  neg D-Arabitol:  neg Glycerol:  neg Inositol:  neg Mannitol:  neg Sorbitol:  neg Salicin:  neg
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Urease:  neg α-Fucosidase:  neg α-Galactosidase:  vr α-Glucosidase:  + β-Glucosidase:  neg β-Glucuronidase:  neg α-Mannosidase:  neg β-Mannosidase:  neg ArgDH:  vr GluDC:  neg AlanineAA:  neg AlaPheProAA:  neg GluGluAA:  neg GlyAA:  neg LeuAA:  + LeuGlyAA:  neg PyrrolidAA:  neg AlkalineP:  neg AcidP:  + Esterase(C4):  neg EstLip(C8):  neg Lipase(C14):  neg
    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    		Acetate:  Major(+) Butyrate:  + Lactate:  + H2S:  neg Pyruvate:  minor(+) Indole:  neg
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    ampicillin:  S(MIC50): 0.06, MIC90: 0.5, RNG: (0.06-1)
    amp-sulb:  S(MIC50): 0.25, MIC90: 0.5, RNG: (0.06–0.5)
    piper-taz:  S(MIC50): 0.25, MIC90: 1, RNG: (0.015–1)
    imipenem:  S(MIC50): 0.06, MIC90: 0.25, RNG: (0.015–0.5)
    meropenem:  S(MIC50): 0.06, MIC90: 0.25, RNG: (0.03–0.25)
    cefoxitin:  S(MIC50): 2, MIC90: 8, RNG: (0.125–16)
    ceftazidime:  R(MIC50): 8, MIC90: 32, RNG: (0.25–32)
    fidaxomicin:  Var(MIC50): 2, MIC90: >32, RNG: (0.125–>32)
    linezolid:  S(MIC50): 1, MIC90: 4, RNG: (0.25–8)
    moxifloxacin:  S(MIC50): 0.5, MIC90: 1, RNG: (0.06–8)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    tigecycline:  S(MIC50): 0.125, MIC90: 0.5, RNG: (0.125–0.5)
    vancomycin:  S(MIC50): 0.5, MIC90: 1, RNG: (0.25–4)
    metronidazole:  S(MIC50): 0.5, MIC90: 2, RNG: (0.125–4)
    clindamycin:  S(MIC50): 0.06, MIC90: 2, RNG: (0.06–>128)
    daptomycin:  Var(MIC50): 0.5, MIC90: 16, RNG: (0.06–32)

    References

    SPECIFIC REFERENCES FOR SOLOBACTERIUM MOOREI
  • Kageyama2000c - Phylogenic and Phenotypic Characterization of Some Eubacterium-Like Isolates from Human Feces: Description of Solobacterium moorei gen. nov., sp. nov.
  • Kageyama2011Bergey - Bergey's manual of systematic bacteriology. Vol. 3, The Firmicutes. Family Erysipelotrichaceae, Genus VII. Solobacterium
  • Chen2020a - Featured Gut Microbiomes Associated With the Progression of Chronic Hepatitis B Disease
  • Jackson2016 - Signatures of early frailty in the gut microbiota
  • Jie2017 - The gut microbiome in atherosclerotic cardiovascular disease
  • Liu2016a - Remodeling of the gut microbiota and structural shifts in Preeclampsia patients in South China
  • Yachida2019 - Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer
  • Yang2020a - Establishing high-accuracy biomarkers for colorectal cancer by comparing fecal microbiomes in patients with healthy families
  • Yu2015 - Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer
  • Goldstein2018a - Comparative In Vitro Activities of Relebactam, Imipenem, the Combination of the Two, and Six Comparator Antimicrobial Agents against 432 Strains of Anaerobic Organisms, Including Imipenem-Resistant Strains.
  • Goldstein2013b - Comparative in vitro activities of GSK2251052, a novel boron-containing leucyl-tRNA synthetase inhibitor, against 916 anaerobic organisms.
  • Tyrrell2012 - In vitro activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic, against 377 strains of anaerobic bacteria and 34 strains of Corynebacterium species.
  • Citron2012a - Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria.
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR SOLOBACTERIUM MOOREI
  • Byrd2020 - Stability and dynamics of the human gut microbiome and its association with systemic immune traits.
  • Chen2020 - Structural and Functional Characterization of the Gut Microbiota in Elderly Women With Migraine
  • Chen2020a - Featured Gut Microbiomes Associated With the Progression of Chronic Hepatitis B Disease
  • Dubinkina2017 - Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease
  • Hu2019 - The Gut Microbiome Signatures Discriminate Healthy From Pulmonary Tuberculosis Patients
  • Jie2017 - The gut microbiome in atherosclerotic cardiovascular disease
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • PerezBrocal2015 - Metagenomic Analysis of Crohn's Disease Patients Identifies Changes in the Virome and Microbiome Related to Disease Status and Therapy, and Detects Potential Interactions and Biomarkers
  • RajilicStojanovic2014 - The first 1000 cultured species of the human gastrointestinal microbiota.
  • Salonen2014 - Impact of diet and individual variation on intestinal microbiota composition and fermentation products in obese men.
  • Walker2011 - High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease.
  • Yang2020 - Species-Level Analysis of Human Gut Microbiota With Metataxonomics.
  • Yang2020a - Establishing high-accuracy biomarkers for colorectal cancer by comparing fecal microbiomes in patients with healthy families
  • Zeller2014 - Potential of fecal microbiota for early-stage detection of colorectal cancer
  • Zou2019 - 1,520 reference genomes from cultivated human gut bacteria enable functional microbiome analyses.
  • ...............................
    • GENERAL REFERENCES FOR SOLOBACTERIUM MOOREI
  • Ludwig2009 - Revised road map to the phylum Firmicutes.
    • Added: April 08, 2021